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Abstract.  Since a number of anti-glycosphingolipid 
(GSL) antibody activities have been demonstrated in 
patients with various neurological disorders,  the pres- 
ence of common antigens between brain microvascular 
endothelial cells (BMECs) and the nervous tissues 
presents a potential mechanism for the penetration of 
macromolecules from the circulation to the nervous 
system parenchyma.  We first investigated GSL compo- 
sition of cultured bovine BMECs. Bovine BMECs ex- 
press GM3(NeuAc) and GM3(NeuGc) as the major 
gangliosides,  and GM1, GDla,  GDlb, GTlb, as well as 
sialyl paragloboside and sialyl lactosaminylparaglobo- 
side as the minor species. Sulfoglucuronosyl 
paragloboside was also found to be a component of 
the BMEC acidic GSL fraction, but its concentration 
was lower in older cultures.  On the other hand,  the 
amounts of neutral GSLs were extremely low, consist- 
ing primarily of glucosylceramide. In addition,  we 
analyzed the effect of anti-SGPG IgM antibody ob- 
tained from a patient of demyelinative polyneuropathy 
with macroglobulinemia against cultured BMECs. Per- 
meability studies utilizing cocultured BMEC 
monolayers and rat astrocytes revealed that the anti- 
body facilitated the leakage of [carboxy-~4C]-inulin  and 
~25I-labeled human IgM through BMEC monolayers. A 
direct cytotoxicity of this antibody against BMECs 
was also shown by a leakage study using p1Cr]- 
incorporated BMECs.  This cytotoxicity depended on 
the concentration of the IgM antibody, and was almost 
completely blocked by preincubation with the pure an- 
tigen,  sulfoglucuronosyl paragloboside. Our present 
study strongly supports the concept that immunologi- 
cal insults against BMECs induce the destruction or 
malfunction of the blood-nerve barrier,  resulting in 
the penetration of the immunoglobulin molecule to at- 
tach peripheral  nerve parenchyma. 
T 
HE vascular endothelial  cells (ECs) ~ are highly  ver- 
satile  cells  and  are  structurally  and  metabolically 
involved in various barrier functions. The characteris- 
tic features  of ECs include the presence of a nonthrombo- 
genic luminal  surface,  expression  of von Willebrand  factor, 
prostacycline,  and endothelin,  and  formation  of a  highly 
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GSL structures  are abbreviated  to the IUPAC-IUB recommendations 
(1977) except gangUo-series gangliosides, which are abbreviated according 
to Svennerholm (1964). 
1. Abbreviations used in this paper: BBB, blood-brain barrier; bFGF, basic 
fibroblast  growth  factor;  BMEC,  brain  microvaseular  endothelial  cell; 
BNB, blood-nerve barrier;  DM, dissecting media;  EC,  endothelial  cell; 
GSL, glycesphingolipid; HPTLC, high-performance thin-layer chromatog- 
raphy;  MAG, myelin-associated  glycoprotein;  SGGL,  sulfoglucuronosyl 
glycolipid;  SGPG,  sulfoglucuronosyl paragloboside,  IV3HSO3-Glc-UAn  - 
Lc4Cer; SGLPG, sulfoglucuronosyl lactosaminyl paragloboside, VI3HSO3  - 
GIcUAnLe6Cer;  SPG,  sialyl  paragloboside,  IV3NeuAenLc4Cer;  SLPG, 
sialyl lactosaminyl paraglobeside, VI3NeuAcnI~Cer;  sialyl Lewis  x, 1V3Neu  - 
AcIH3FucnLc4Cer. 
selective barrier to the passage of plasma constituents  into 
the tissue parenchyma.  ECs are functionally  as well as mor- 
phologically heterogeneous in various tissues, and this prop- 
erty is very important for their specialized  function  in in- 
dividual  tissue  and  organ  function.  Brain  microvascular 
endothelial cells (BMECs) are highly specialized cells in this 
respect and are considered to make up the structural  basis 
of the blood-brain barrier (BBB) and blood-nerve barrier 
(BNB). Since BMECs are the only cell groups in the nervous 
system which are continuously exposed to blood constitu- 
ents, the information  conveyed via the surface receptors on 
BMECs are considered to be very important for the regula- 
tion of BBB/BNB function and, subsequently, for the homeo- 
stasis of various cations, nutrients,  and growth factors in the 
central  and peripheral nervous  systems. 
Gangliosides are siaiic acid-containing  glycosphingolipids 
(GSLs)  and  are  located  almost  exclusively  on  the  outer 
leaflet of the plasma membrane. They have been implicated 
in many cell surface phenomena (Hakomori, 1981), includ- 
ing cellular recognition  and adhesion,  cellular  communica- 
tion, and modulation of immune responses; hence,  knowl- 
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and receptors in BMEC is of crucial importance to the un- 
derstanding of the pathogenesis of nervous system disorders 
affecting BBB/BNB.  Because a  number of anti-GSL anti- 
body activities have been demonstrated in patients with vari- 
ous neurological disorders (Yu et al., 1993),  the presence of 
common antigens between BMECs and the nervous tissues 
presents a potential mechanism for the penetration of  macro- 
molecules from the circulation to the nervous system paren- 
chyma. However,  information on the GSL composition in 
ECs  is  limited to  human umbilical cord vein EC  so  far 
(Gillard et al.,  1987),  and no work has been performed on 
BMECs. 
We recently developed a method to yield sufficient quanti- 
ties of highly purified bovine BMECs for biochemical analy- 
ses. One of the aims of the present study is to determine the 
GSL composition of cultured bovine BMECs. In addition, 
we demonstrate the immunological attack of anti-sulfoglu- 
curonosyl  glycolipid  (SGGL)  monoclonal  IgM  obtained 
from  a  patient  with  demyelinative  neuropathy  against 
BMECs, using our in vitro model of BBB/BNB and [5~Cr]- 
incorporated BMEC monolayer. 
Materials and Methods 
Culture Media for BMECs 
Dissecting medium (DM): Medium 199 (GIBCO BRL, Grand Island, NY) 
supplemented  with  5%  equine  plasma-derived  serum  (EPDS)  (Sigma 
Chemical Co., St. Louis, MO), 20 mM sodium bicarbonate, 50 #g/mi hepa- 
fin  (Sigma  Chemical Co.),  I00 U/ml penicillin,  I00 #g/ml streptomycin, 
25  ng/ml  amphotericin  B (GIBCO BRL), and  20  mM  N-[2-hydroxyethyl]- 
piperazine-N'-[2-ethanesulfonic  acid](Hepes; pH  7.2). Bovine BMEC 
growth  medium: DME  (GIBCO BRL) supplemented  with  15% EPDS and 
4% fetal  bovine  serum (BioWhit~aker,  Inc.,  Walkersville,  MD), I ng/mi 
human recombinant basic fibroblast growth factor (bFGF) (Collaborative 
Biomedical Product, Bedford, MA), and 50 #g/ml heparin. Percoll gradi- 
ent: 43 ml of percoll (Pharmacia Fine Chemicals, Piscataway, NJ), 5 ml of 
10x  Medium 199,  1.5 ml of 1 M  Hepes,  0.5 ml of 100x  antibiotic anti- 
mycotic solution, 50 nd of DM with 10% of EPDS. The solution was mixed 
well,  aliquoted to 50-ml Oak Ridge centrifuge tubes, and centrifuged at 
25,100 g in a fixed angle rotor for 70 min (Beckman JA-17; Beckman Instrs., 
Carlsbad,  CA). 
Isolation of  BMECs 
Isolation of bovine BMECs was achieved using a modified method of Gor- 
don et al. (1991),  which was originally designed for rat capillary endothelial 
cells.  Bovine brains were removed from freshly killed animals at a local 
slaughterhouse and delivered to the laboratory at 4°C.  They were rinsed 
twice with DM,  and the pia mater and surface vessels were carefully re- 
moved using fine forceps.  The cerebral cortex was then minced to 2- to 
3-mm  cubes,  rinsed  several  times  in  DM,  and  homogenized  using  a 
Wheaton-Dounce Teflon homogenizer.  The homogenate was further dis- 
sociated  with 0.005%  (wt/vol)  dispase  (grade  1,  Boebringer Mannheim 
Corp.,  Indianapolis, IN) in DM at 370C for 2 h  in a  shaking water bath. 
After centrifugation (800 g, 5 win), the pellet was suspended with a dextran 
solution (mol wt 70,000;  15% wt/vol in DM; Sigma Chemical Co.),  and 
the whole suspension was centrifuged (40C, 4,500 g  for 10 min, using a 
Beckman JS 13.1 swinging bucket rotor). The pellet was resuspended with 
the  dextran  solution,  and  centrifuged  again.  After  two  centrifugations, 
microvessels and some single cells including red blood cells were obtained 
in the pellet. The undesirable fractions including myelin and brain paren- 
chyma were floated. The pellet was recovered with DM and filtered through 
a  130-/~n nylon mesh (Nitex; Tetko Inc., Elmsford, NY) to remove large 
vessels. The filtrate was further digested using collagenase/dispase [0.035% 
(wt/vol) in 10 ml DM; Boehringer Mannheim Corp.] at 370C,  for 12 h in 
a  shaking water bath. The collagenase dispase-treated microvessels were 
centrifuged and suspended in 1.0 rul DM, layered across the top of a Pereoll 
gradient and centrifuged at 4°C, 1,650 g, for 10 rain. EC clusters were pres- 
ent in approximately the middle third of the gradient (just below the thick 
band consisting of cell debris and single cells),  and were  collected  and 
washed twice in DM to remove Percoll. They were filtered through double 
layers of 15-#m mesh to remove single cells, which were the largest sources 
of non ECs, and the unfiltered cell clusters were placed into type I collagen 
(Collaborative Biomedical Products,  Bedford,  MA) coated dishes.  Cells 
were maintained at 37°C in an atmosphere of 5% CO2 in a humidified in- 
cubator.  The medium was changed three times a week. 
After 18 h, the first migrated ECs were observed. When the EC colonies 
grew sufficiently large for cloning (usually more than 100 EC cells), the 
medium was replaced by 0.25%  pancreatin solution (OIBCO BRL).  The 
colonies for cloning (free of contamination of non-ECs including pericytes) 
were marked prior to the enzymatic treatment. The colonies were detached 
as clumps of ECs, and the marked colonies were picked up using a Pasteur 
pipete  and  were  briefly dissociated  in 0.1%  trypsin  in Ca  e+,  Mg2+-free 
Hanks' solution for 3-4 min. Cells were inoculated again on 35-mm Petri 
dishes coated with type I rat tail collagen. After 5-12 d, confluent EC cells, 
free of contaminating non-EC cells, were subcultured at a split ratio of 1:10. 
Identification of  BMECs 
BMECs were identified by the following four criteria: a cobblestone-like 
appearance,  immunoreactivity to anti-von Willebrand factor antigen anti- 
body (data not shown),  uptake of DiI-Ac-LDL  (1,  l'-dioctacecyl-3,3,3'3, 
tetramethyl indocarbocyanine pereMorate acetylated low density lipepro- 
tein (Biomedical Technologies Inc., Stoughton, MA) (Voyta et al.,  1984), 
and the ability to adhere to leukocytes or myeloid cells after stimulation 
with inflammatory cytokines such as interleukin lB. To label with DiI-Ac- 
LDL, cells were incubated with 10 #g/ml of DiI-Ac-LDL at 37°C in normal 
media for 4 h. The cells were then washed once with probe-free media for 
10 rain, fixed with 4% paraformaldehyde for 30 min, and viewed under a 
fluorescent microscope.  BMECs  showed cobblestone appearance and in- 
corporated the bright DiI-Ac-LDL particles into their cytoplasm (Fig.  l). 
Figure 1.  Staining of BMECs  with  DiI-Ac-LDL.  (,4)  Fluorescent 
micrograph;  (B) phase contrast micrograph of the same field. Bar, 
100 ~zm. 
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Adhesion  of  HL-60  cells,  known  to  possess  sialyl  Lewis  x  (IV  3 
NeuAcfi/3FucnLc4Cer) antigen which has  been shown to  be a  specific 
ligand for E-selectin (Phillips et al.,  1990)  on activated BMECs, was as- 
sayed. The BMECs monolayer, contluently grown in a collagen-coated 24- 
well plate, was stimulated with 5 ng/ml of human recombinant interleukin 
1/~  (Beckton-Diekinson, Franklin  Lakes,  NJ).  Four hours later,  HL-60 
cells (1.0 ×  106/0.5 mi/well) were added and incubated for 20 rain with ro- 
tation (100 rpm) at room temperature. The number of attached cells were 
counted directly under light microscopy. Significantly larger number of  HL- 
60 cells attached to stimulated BMECs (12310  -t-  1050/mm2;  Fig. 2 A) 
than to nonstimulated BMECs (410  -t- 60/mm2; Fig. 2 B). 
Adhesion of human ieukocytes to activated BMEC monolayer was also 
investigated. Leukocytes were isolated by Histopague-1077 (Sigma Chemi- 
cal Co.) density gradient centrifugation of  EDTA-treated blood from healthy 
volunteers. Four hours after stimulation with interleukin  1/~, leukocytes 
(0.25  ×  106/0.5 ml/well) were added and incubated for 20 min with rota- 
tion (100 rpm) at room temperature. Then the cells were fixed with 2.5% 
glutaraldehyde overnight and the number of cells attached to the surface of 
BMEC monolayer was counted. Significantly larger numbers of leukocytes 
was attached to the interleukin $-stimniated BMEC  (P <  0.05,  1250  + 
280/mm  2 vs. 200  +  20/mm2; Fig. 2  C and 2 D). 
Isolation of Glycosphingolipids 
Cultured BMECs, confluently grown and '~1  ×  107 cells in number, were 
harvested by scraping from the petri dishes, washed two times with PBS, 
pH 7.3, and homogenized in 0.5 mi of distilled water.  Cells grown in vitro 
from days 14-35 were used for GSL analysis, except for the quantitation 
of SGGLs. The latter was performed utilizing cultures of 7 or 14 d in vitro 
because SGGLs became undetectable on TLC plate after long period of  cul- 
tivation. Protein contents were determined by the method of Lowry et al. 
(1951). Lipids were extracted with 5 ml of  chloroform/methanol (1:1 by vol- 
ume), and 5 ml of  chloroform/methanol (1:2 by volume), successively. After 
evaporating the organic solvents under a nitrogen stream, the lipids were 
dissolved in 0.5 ml of chloroform/methanol/water (30:60:8 by volume; sol- 
vent A), and applied to a Sephadex LH-20 column (0.5  ×  48 cm, 25-ml 
bed volume; Pharmacia Fine Chemicals), pre-equilibrated with solvent A. 
After the first 8 mi of  the effluent was discarded, the next 8 ml of  the effluent 
was collected as a GSL fraction. The GSL fraction was then applied to a 
DEAE-Sephadex A-25 column (2.0-mi bed volume; Pharmacia Fine Chem- 
icals). The neutral GSL fraction was eluted with 10 ml of solvent A and 
10 ml of methanol, and the acidic GSL fraction was eluted with 10 ml of 
0.2 M sodium acetate in methanol and 0.4 M sodium acetate in methanol. 
The acidic lipid fraction was evaporated to dryness and the residue was dis- 
solved in 0.5 mi of  solvent A, and then desalted by Sephadex LH-20 column 
as described above. The recovered gangliosides and SGGLs were developed 
on a high-performance thin-layer chromatographic plate (HPTLC; Merck, 
Darmstadt,  Germany)  with the solvent system of chloroform/methanol/ 
water containing 0.22% CaC12.2H20  (50:45:10 by volume, solvent system 
I) or chloroform methanol 5N ammonia 0.4% CaCI2.2H20 (50:45:5:5 by 
volume, solvent system II), and were visualized by spraying the plate with 
the resorcinol-HCl or orcinol-sulfuric acid reagent (Ando et al.,  1978; 
Sekine et al.,  1984). 
The neutral GSL fraction was evaporated to dryness. The residue was 
subjected to aeetylation according to the method of  Handa (1963) to remove 
the phospholipids. The acetylated GSLs were purified by Iatrobeads column 
chromatography (0.5  ×  10 cm) by stepwise elution with 10 mi each of  chlo- 
roform n-hexane (1:1 by volume), chloroform, chloroform methanol (4:1 by 
volume), and chloroform methanol (2:1 by volume). The acetylated GSLs 
were eluted with chloroform methanol (4:1  by volume). The eluant was 
evaporated to dryness and the residue was subjected to mild alkaline treat- 
ment (0.5 mi of  0.4N NaOH in methanol) at 40"C for 2 h. The reaction mix- 
tures were applied to a  Sephadex LH-20 column to remove salts as de- 
scribed above. Neutral GSL composition was examined by HPTLC. Prior 
to chromatography, the upper half of  the plate was sprayed with 1% sodium 
borate and the entire plate was activated for 30 rain at 120"C.  Following 
application of the sample, the plate was developed with the solvent system 
of  chloroform/methanol/water  (65: 35:5 by volume, solvent system  III). The 
neutral GSLs were visualized by spraying with the orcinol-sulfuric acid re- 
agent. 
Figure 2.  Attachment of HL-60 cells (A) and (B), and human leukocytes (C) and (D) to the surface of BMECs.  (A) Activated and (B) 
nonactivated BMECs (HL-60 cells). (C) Activated and (D) nonactivated BMECs (human leukocytes). Pictures C  and D  were taken after 
overnight fixation with 2.5 % glutaraldehyde.  Bar,  100/~m. 
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Immunostaining of gangliosides was performed on an HPTLC plate as de- 
scribed p~viously (Kasai et al.,  1984).  The acidic GSL fractions of the 
brain, BMEC and standard GM3 (GM3[NeuAc] and GM3 [NeuGc] from 
bovine adrenal medulla [Ariga et al., 1984]) were developed on an HPTLC 
plate in the solvent systems as described above. The plate was then dipped 
in a 0.2%  polyisobutylmethacrylate (Aldrich Chemical Co., Milwaukee, 
WI) solution in bexane for 30 s. After drying the plate in air, the plate was 
overlaid with an avian polyclonal antibody against GM3(NeuGc) (courtesy 
of Dr. N. Kasai, Hokkaido University, Japan) at a dilution of 1:200 with 
PBS containing 0.3% gelatin (dilution buffer) at 4°C overnight. The plate 
was then incubated with peroxidase-conjngated goat anti-rabbit immuno- 
globulin antibody (Cappel, West Chester, PA) at a dilution of 1:200 for 1 h 
at room temperature. Gangliosides were visualized with a PBS solution con- 
taining 0.5% 4-chloro-l-naphtol and 0.01% HzO:. 
Quantification of Gangliosides 
The content of GM3 was determined by densitometric scanning of the chro- 
matographic plate visualized with the resorcinol-HCl reagent as described 
previously (Ando et al., 1978).  Because the amounts of gangliosides other 
than GM3 were below the detection limit of the resorcinol-HCl reagent, 
quantification of these gangliosides was performed using more sensitive 
ligands and specific antibodies against each GSL as described below. The 
content of gangliotetraose-series  gangliosides including GM1 and GDla and 
neolacto-series  gangliosides were determined by the GSL-overlay technique 
with in  situ treatment of gangliosides with sialidase and cholera toxin 
B-subunit (List Biological Labs.  Inc.,  Campbell,  CA) or an anti-para- 
globoside antibody (Myoga et al., 1988) (kindly provided by Dr. T. Taki) as 
described previously (Saito et ai., 1985; Miyatani et al., 1990a). The chro- 
matogram obtained was scanned by a Shimadzu CS-910 scanning densitom- 
eter equipped with a Shimadzu CR1A data processor (Shimadzu Scientific 
Co., Kyoto, Japan) at 580 nm in a reflectance mode. Each ganglioside was 
quantitated based on the standard curves obtained from the standard gan- 
gliosides developed on the same plate. 
Immunocytochemistry of GM3(NeuAc) 
Cultured BMECs on 35-ram dishes were fixed with 4% paraformaldehyde 
for 15 min and washed with PBS at least three times. After incubation in 
PBS with 3 % nonimmunized rabbit serum, rat polyclonal anti-GM3(NeuAc) 
antibody, diluted 1:100 in PBS, was applied at 4"C for 72 h. The dishes were 
washed three times and peroxidase-conjugated  rabbit anti-rat immunoglob- 
ulin Ab (Cappel, 1:200 dilution) was applied for 1 h at room temperature. 
Then  the  dish  was  incubated  in  diaminobenzidine  tetrahydrochloride 
(Sigma Chemical Co.; 600/~g/ml in PBS with 0.03 % H202)  for 5 min to 
visualize the labeled sites. 
Monoclonal lgM that Reacts with SGGLs 
The serum from a patient with demyelinative neuropathy and IgM parapro- 
teinemia (LT-serum) was provided by Dr.  A.  Pachner (Yale  University 
School of Medicine, New Haven, CT). This monoclonal IgM recognizes 
a  carbohydrate epitope that is shared by myelin-associated glycoprotein 
(MAG) (Braun et al., 1982), a group of low molecular weight glycoproteins 
in peripheral nerve (Inuzuka et al.,  1984),  glycoproteins of the N-CAM 
family (Kruse et al.,  1984,  1985),  human natural killer cells (Schuiler- 
Petrovic et al.,  1983),  and at least three acidic GSLs, sulfoglucuronosyl 
paragloboside  (SGPG),  sulfoglucuronosyl  lactosaminyl  paragloboside 
(SGLPG), and band X (Chou et al., 1986; Ariga et al., 1987; Kusunoki et 
al., 1987).  The anti-MAG and anti-SGGL activities of this serum were ex- 
amined by an immunoblot technique and HPTLC-immunostaining method, 
respectively (Kohriyama et al., 1987).  A purified IgM preparation was ob- 
tained from the ammonium sulfate precipitation of the LT serum (LT-IgM). 
The precipitate was dialyzed against water, and the IgM fraction was finally 
separated by Sephacryl G-300 (Pharmacial Fine Chemicals) and freeze- 
dried. Control human IgM was purchased from Sigma Chemical Co. It was 
also dialyzed against water and freeze-dried. 
Quantification of SGPG 
The total GSL fraction, including both acidic and neutral GSLs, was ap- 
plied directly to an HPTLC plate (Yoshino et al., 1993). Quantitative analy- 
sis of SGGLs was achieved by the method described previously (Kohriyama 
et al., 1987) with slight modifications. After the GSL fraction and authentic 
SGPG (from 2 to 120 ng in quantity) were chromatographed in the solvent 
system I, the plate was dipped in 0.2% polyisobutylmethacrylate solution 
in bexanE for 30 s and air dried. The the plate was incubated with LT-serum 
at a dilution of 1:1,000 in dilution buffer, followed by peroxidase conjugated 
rabbit anti-human IgM (#-chain specific, 1:1,000; CappeD. The plate was 
incubated with cyclic diacylhydrazide solution (Amersham Corp., Arling- 
ton Heights, IL) for 1 min and exposed on an x-ray film for 15 s. SGPG 
was quantitated based on the standard curves generated by densitometric 
scanning of known amounts of SGPG developed on the same plate. 
Sulfate Incorporation into BMEC Monolayer 
BMEC monolayer (in vitro 45 d, confiuentty grown on 60-mm culture dish) 
was incubated with 1 mCi of [35S]-Na:SO4 (New England Nuclear, Bos- 
ton, MA) for 24 h at 37"C and harvested. Total lipids were then extracted 
from the homogenized cells as described above and the GSL-fraction was 
cochromatographed with authentic SGPG and the acidic lipid fraction ob- 
tained from bovine canda equlna in two different solvent systems I and II. 
Then the plate was exposed to an x-ray film for 72 h and immunostained 
with LT-serum as described above. 
Immunostaining of  Living BMECs with LT-IgM 
BMECs  grown  on  collagen-coated  35-mm  petri  dishes  (Beckton- 
Dickinson) was incubated with heat-inactivated EC media containing 0.1% 
LT-IgM for 1 h. After washing three times with Hanks' solution, cells were 
further incubated in heat-inactivated EC media containing FITC-conjugated 
rabbit anti-human IgM (p-chain specific, 1:40 dilution; Dako, Carpinteria, 
CA) for 30 min. BMECs were washed three times with Hanks' solution and 
immediately fixed with 4% paraformaldehyde for 15 min. 
12sI-labeling of  Normal and Patient's IgM 
A portion of the freeze-dried IgM from LT-serum and control was [125I]- 
iodinized according to the method of Bolton and Hunter (1973),  using the 
Bolton-Hunter reagent, N-succinimidyl 3-(4 hydroxy, 5-[125I]iodopbenyl) 
proprionate, purchased from Amersham Corp. The iodinated IgM fraction 
was desalted with a PD-10 column (Pharmacia Fine Chemicals). 
Isolation and Culture of  Rat Astrocytes 
Primary cultures of astrocytes were prepared from newborn rat cerebral 
cortex using a modified method of McCarthy and de Vellis (1980). The cere- 
bral hemispheres were aseptically removed from newborn (Sprague-Dawley, 
postnatal days 1-2) rats and placed into ice-cooled Ca  2+, Mg2+-free Hanks' 
solution. The meninges were carefully removed and the hemispheres were 
minced into small fragments. After incubation in 0.005 % dispase (Boeh- 
ringer Mannheim Corp.) solution for 2 h at 37"C, the tissue was centrifuged 
at 150 g for 3 min, and the supernatant was replaced with DME supple- 
mented with 10% FBS. The digested tissue was then dissociated by tritura- 
tion 15 times with a Pasteur pipote, filtered through a  125-#m nylon mesh 
screen (Tetko,  Inc.), and seeded into 75-cm  2 culture flasks (Falcon Plas- 
tics, Cockeysville, MD). Cells were maintained in an atmosphere of 5 % 
CO2  in a  humidified incubator. The medium was chaiaged' three times a 
week. After 7--9 d in vitro, the flasks were filled Wi'th fiat astrocytes and 
small,  round oligodandrocyte prec~rs  (OA-2  pr0ge.nitors).  The flasks 
were vigorously shaken (200 rpm) on an orbital shaker (Lab-line Instru- 
ments, Melrose Park, IL) for 48 h to detach loosely atta'ehed  OA-~ progeni- 
tors and macrophages. The media containing detached cells were discarded 
and the cells still remaining at the bottom (almost 95 % as astrocytes) were 
used for coculture with BMECs or temporarily stored in liquid nitrogen. 
Coculture of  Bovine BMECs and Rat Astrocytes 
Fig. 3 shows the schematic drawing of the BMEC/astrocyte coculture sys- 
tem.  ECs obtained from brain microvessels are known to gain high im- 
pedance and mimic the actual BMECs making up the BBB and BNB in vivo 
when cocultured with astrocytes (Meresse et al., 1989; Rubin et al., 1991). 
Both (luminal and abluminal) sides of the culture plate inserts (Millicell- 
CM, pore size 0.4 #m, 30 mm in diameter; Milipore, Bedford, MA) were 
coated with rat tail collagen type I (Collaborative Biomedical Products) and 
human fibronectin (Biomedical Technologies Inc.). Astrocytes were plated 
at a density of 1 x  106 cells/insert on the bottom side with the filter placed 
upside down. After 8 h, the filters were properly positioned in 6-well culture 
plates (Beckton-Dickinson) and were examined to ensure complete cover- 
age by cultured astrocytes. 7 to  10 d after plating, bovine BMECs were 
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Figure 3. Schematic drawing of  the experimental system for perme- 
ability study. Rat tail type I collagen- and human fibronectin-coated 
membrane was sandwitched between BMEC monolayer and rat as- 
trocytes. Neither cells can traverse to the other side because of the 
small (0.4 #m) pore size of the membrane. This system mimics the 
actual brain microvascular system in vivo because the BMECs were 
closely cultured but not directly in touch with astrocytes and the 
challenged  substances  always  came  from  the  upper  chamber, 
equivalent to the intraluminal space of the capillaries in vivo. 
seeded  on the upper  side  of the filter  at a  concentration  of 5  x  105 
cells/insert and the media was changed to EC media. These cocuitures were 
used for [carboxy-14C]-inulin  or [125I]-IgM flux determinations after 7 d. 
The electric resistance across BMECs cultures on Millicell-CM was mea- 
sured  with  a  WPI  EVOM  apparatus  (World Precision  Instruments, 
Sarasota,  FL).  The resistance of the filter with astrocytes was subtracted 
from the resistance  of the cocultures to obtain the resistance due to the 
BMEC monolayers themselves. The resistance of  these monolayers after 7 d 
of coculture averaged 439 +  107 ohm.cm  2 (mean +  SD; n =  22)and only 
the BMEC monolayer which had a resistance of more than 350 ohm.cm  2 
were utilized for flux measurements. 
Flux Measurements and Data Analysis 
The upper compartment was incubated with test media (0.1% LT-IgM or 
control IgM in heat-inactivated EC media), with or without 20% fresh hu- 
man serum as a source of  complement for 3 h. After washing two times with 
DME, 2.5 ttCi of [carboxyl-t4C]-inulin (New England Nuclear) in 2.5 ml 
of EC media was added to the upper compartment.  The appearance  of 
[carboxyl-14C]-inulin in the lower chamber was measured at various times 
(0, 10, 20, 30, 40, and 60 min) thereafter by scintillation counting of 100-t~l 
Figure 5.  Immunocytochemistry with the anti-GM3(NeuAc) anti- 
body. All cells grown in the monolayer were immunostained  by this 
antibody. Bar,  100 #m. 
aliquots of upper and lower chambers. For comparison, the flux across the 
EC-free filters were also measured. Care was taken to make sure that the 
fluid levels in the two chambers were equal (2.5 ml in the upper chamber 
and 3.0 ml in the lower). The chambers were kept at 37°C during the whole 
course of the experiment, and stirred (30 rpm, using an orbital shaker) to 
ensure uniform distribution  of [carboxyl-14C]-inulin traversed across the 
membrane. 
The clearance of [earboxyl-14C]-inulin  was obtained as a measure of en- 
dothelial permeability. The clearance (in/~1) of inulin (Cinu) was calculated 
as follows: Cinu  =  VL*CPML/CPMu, where VL is the volume of the lower 
compartment  in #1, CPML is radioactivity of [carboxy-14C]-inulin  in the 
lower chamber  in CPM/#I, and CPMu is the radioactivity of [earboxy- 
14C]-inulin in  the upper compartment  in  CPM/#I.  The  clearance  rate 
(#l/min) was calculated by fitting the measured clearance for a single experi- 
ment to a straight line by least squares linear regression. The flux of [l~I]- 
IgM was also measured in the same manner. After incubation with the test 
media, ~50,000  cpm of [125I]-IgM (LT or normal) was added to the upper 
compartment and the appearance of [t25I]-IgM in the lower chamber was 
estimated at various times by measuring  100-#1 aliquots with a gamma 
counter. 
~Cr Release Assay 
The confluent monolayers of BMECs in 24-well multiple plates were in- 
cubated for 18 h with the EC media supplemented with 5/~Ci/ml of [5tCr]- 
sodium chromate (1 mCi/ml in saline, 250-500  mCi/mg; 0.4 nil/well; New 
England Nuclear). Each well was washed two times with DME to remove 
Figure  4.  HPTLC-immuno- 
staining  with  the  anti-GM3 
(NeuGc)  antibody.  Lane  1, 
human brain ganglioside stan- 
dards; lane 2, BMEC ganglio- 
sides; lane 3,  standard GM3 
(NeuAc);  lane  4,  standard 
GM3(NeuGc).  A  was  devel- 
oped in the solvent system I. B 
and C  were developed in the 
solvent system II.  The bands 
of A  and  B  were  visualized 
with  the  resorcinol-HC1  re- 
agent.  The bands of C  were 
immunostained  with  anti- 
GM3  (NeuGc) antibody. 
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HPTLC-immunostaining of (A) SPG and SLPG and (B) ganglio- 
tetraose-series gangliosides in BMEC. Lane 1, human brain gan- 
glioside  standards  were visualized with the  resorcinol-HCl  re- 
agent;  lanes  2-4, 0.1, 0.3, and  1.0  umol  of  standard  SPG 
(IV3NeuAcnLc4Cer) and  SLPG  (VPNeuAcnLctCer),  respec- 
tively; lane 5, BMEC gangliosides. The bands in lanes 2-5 were 
immunostained with  anti-paragloboside antibody after sialidase 
treatment in situ. Lane 6, 1.25 pmol each of GM1 and GDIa, and 
2.5 pmol each of GDIb and GTlb;  lane  7, BMEC gangliosides. 
Gangliotetraose-series gangliosides were detected by cholera toxin 
B-subunit after sialidase treatment in situ. The plates were devel- 
oped in the solvent system I. 
unbound radioactivity. The BMECs were than incubated with 0.4 ml per 
well of heat-inactivated EC media supplemented with: (a) 0.5%  LT-IgM, 
(b) 0.5% LT-IgM plus 20% fresh human serum, (c) 0.1% LT-IgM,  (d) 0.1% 
LT-IgM plus 20%  fresh human serum, (e) 0.5%  normal human IgM, (f) 
0.5% normal human IgM plus 20%  fresh human serum, (g) 0.1% normal 
human IgM, (n) 0.1%  normal human IgM plus 20%  fresh human serum, 
(i) 0.1% Triton X-100 for estimating maximum 5~Cr release, or (]) normal 
EC media for estimating spontaneous 51Cr release. The 100-/zl aliquot of 
incubation  media  was  sampled  from  each  well  and  the  ~Cr  contents 
released in the media were measured with a gamma counter. Fresh human 
serum was used as a source of complements, and the four conditions (e-h) 
with normal human IgM served as controls. The results were expressed as 
percentage of specific release of 51Cr as follows: 
Sample (cpm)  -  Spontaneous 51Cr release (cpm)  x  100 
Maximum 51Cr release (cpm)  -  Spontaneous 51Cr release (cpm) 
Preincubation of  LT-IgM with Sulfoglycosphingolipids 
LT-IgM of various concentrations (from 0.0002%  to 0.1%) was incubated 
for 3 h with a  10 times molar excess of genuine SGPG before application 
on [SICr]-incorporated BMECs. In addition, 0.05%  LT-IgM solution was 
preincubated with a 10 times molar excess of SGPG or sulfatide to compare 
the effect of preincubation with these two sulfated glycosphingolipids. 
Results 
Glycosphingolipid  Composition in BMEC 
Except SGPG, the age of culture in vitro did not affect the 
GSL content significantly in the range of 14 to 35 d. 
Ganglioside Composition  in BMECs.  The total  lipid- 
bound sialic acid was 583 ng per mg protein for the BMECs. 
Fig. 4  shows the ganglioside pattern of the BMECs.  Only 
three major gangliosides were observed in the general area 
of authentic GM3 using the neutral solvent system I (Fig. 4 
A, lane 2). Other minor gangliosides included one slightly 
above GM1, and another slightly above GDIa. By using the 
solvent system II,  the  two  major bands  appeared  as  two 
doublets which had the same mobilities as authentic GM3- 
(NeuAc)  and  GM3(NeuGc) (Fig.  4  B,  lane 2).  The anti- 
body against GM3(NeuGc) reacted with the lower doublet 
as well as standard GM3(NeuGc) but did not react with the 
upper doublet or authentic GM3(NeuAc) (Fig. 4  C).  This 
suggests that the major gangliosides in BMECs consist of 
GM3(NeuAc)  and  GM3(NeuGc).  The  identity  of GM3- 
(NeuAc) in BMECs was confirmed by immunocytochemical 
staining  with a  polyclonal antibody against  GM3(NeuAc) 
(Fig. 5). Since bovine BMEC GM3 contains both N-acetyl 
and N-glycolyl neuraminic acid as shown above, these triple 
bands are presumably due to the presence of different sialic 
acid species as well as different fatty acids (Sekine et al., 
1984). 
The  antibody  against  paragloboside  recognized  three 
bands in the area around SPG and SLPG after treatment of 
the parent GSLs with sialidase in situ (Fig. 6 A). After in situ 
sialidase treatment of the gangliosides on the HPTLC plate, 
cholera toxin B-subunit recognized four gangliosides, which 
corresponded to authentic GM1,  GDla,  GDIb,  and GTlb. 
This suggests that BMECs express these four gangliotetra- 
ose-series gangliosides as minor components (Fig. 6 B). The 
amounts of  these gangliosides, were smaller than those of the 
neolacto-series gangliosides  such  as  sialyl  paragloboside 
(SPG) or sialyl lactosaminyl paragloboside (SLPG) (Table I). 
SGPG in BMECs. SGPG was found in the BMEC GSL 
fraction by the HPTLC-immunostaining method (Fig. 7 A). 
Neither SGLPG nor band X, previously found in human or 
bovine peripheral nerve (Kohriyama et al.,  1987; Kusunoki 
et al.,  1987), could be detected by this method.  Fig.  7  B 
shows the quantitative change of  the amount of SGPG at vari- 
ous in vitro days.  The SGPG content of BMEC decreased 
with increasing age of culture. The concentration of SGPG 
was highest in 7 d samples, but not found in cells after 21 d 
in vitro, using the HTLC-immunostaining methods.  How- 
ever, after 24 h of incubation with 1 mCi of [35S]-Na2SO4 in 
38-d-old BMECs, a positive band was cochromatographed 
with authentic SGPG, suggesting the presence and synthesis 
of SGPG even in aged cultures of BMECs (Fig.  8). 
Neutral Glycolipid Composition of  BMECs 
Neutral GSLs were isolated from confluent BMECs equiva- 
Table L  Glycosphingolipid Composition of 
Cultured BMECs 
Glycosphingolipid  ng/mg protein  n 
GM3(NeuAc)  900 +  152  5 
GM3(NeuGc)  1258 + 212  5 
SPG  66 :t: 25  4 
SLPC  102 + 45  4 
GM1  27 +  10  3 
GDla  27 +  10  3 
GDlb  trace 
GTIb  trace 
SGPG (7d)  65 + 25  5 
SGPG (14d)  21  + 4  5 
GlcCer  379 + 65  4 
Values  were expressed as  ng +  SEM  per  mg  protein,  n,  number  of ex- 
periments. 
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Figure  7.  Quantitation  of 
SGPG in BMECs.  Quantita- 
tion of SGPG was achieved by 
(A)  HPTLC-immunostalning 
of SGPG in BMECs grown in 
vitro, and (B) the concentra- 
tions  in cells  grown in vitro 
for various days.  Lanes  1-3, 
40,  80,  120  ng  of standard 
SGPG,  respectively;  lanes  4 
and 5, BMEC (in vitro 14 d, 
~2  mg  protein)  and  human 
sciatic  nerve  GSL  immuno- 
stained by an anti-SGGL anti- 
body,  respectively.  BMEC 
contained SGPG, but SGLPG 
was not detected.  SGPG could 
not be detected  on TLC plate 
after 21 d in vitro.  The lowest 
detectable  limit  was  about 
1  ng/mg  protein.  The  plate 
was developed  in the solvent 
system I. ND, not detectable. 
lent to 1.5 mg of protein.  Staining with the orcinol-sulfuric 
acid  reagent  revealed  only  two  bands  corresponding  to 
GlcCer (Fig. 9). These double bands are presumably due to 
different fatty acid components (Rauvala, 1976; Ariga et al., 
1982).  Quantitation of these major neutral GSLs were car- 
ried out by gas-liquid chromatography of the trimethylsilyl 
derivatives of the individual  sugar constituents  (Vance and 
Sweeley,  1967).  Glucose,  but not galactose,  was detected 
(data not shown).  The amount of GlcCer was estimated to 
be ~380 ng/mg protein (Table 1). 
Effect of  LT-lgM Against BMECs 
The [carboxyl-14C]-inulin clearance through the empty and 
cocultured inserts challenged by 0.1% IgM was shown in Ta- 
ble II and Fig.  10, a  and b. The [carboxyl-l'C]-inulin clear- 
ance rate (#l/min) through cocultured inserts in control con- 
ditions  (incubated  with 0.1%  normal IgM with or without 
complements) was almost 1/60 of that of the empty inserts, 
indicating that the BMEC monolayer cocultured with astro- 
cytes provided an excellent barrier to [carboxyl-~'C]-inulin 
fluxes (p <  0.05 at all times; Fig.  10 a). Incubation with LT- 
IgM produced a three-to fourfold increase of the [carboxyl- 
l'C]-inulin  clearance  rate  through  membranes  (Table  II), 
but there  was no significant difference between the condi- 
Figure 8. Thin-layer chromatograms of  sulfated glycolipids.  Sulfate 
incorporation into GSL fraction of BMECs (in vitro 8 d).  Lanes 
1,  2,  4,  and  5:  Fluorogram of [35S]-Na2SO4 incorporation into 
BMEC glycolipids.  Lanes 3 and 6: Authentic samples of SGPG and 
SGLPG (1 ng each) immunostained with LT serum. A was devel- 
oped in the solvent system II, and B was developed  in the solvent 
system I.  Radioactivities  in the whole homogenate ranged from 
3,200-4,700 cpm//xg protein and [3sS]-sulfate recovery into GSL 
fraction was 10-17%  of total homogenate. Fluorogram showed at 
least six (A) and five (B) [35S]-incorporated bands.  The 1st band in 
A and the 2nd one in B were cochromatographed with authentic 
SGPG, indicating  the production and presence of SGPG in BMEC 
cultures as old as 38 d in vitro.  There was no band cochromato- 
graphed with SGLPG. 
Figure  9.  Thin-layer  chro- 
matogram  of  neutral  glyco- 
sphingolipids in BMECs. Lane 
1,  1  #g  each  of  authentic 
GalCer  from  human  brain, 
LacCer, Gb3,  Gb4 from por- 
cine erythrocyte membranes, 
and Gb5 from sheep erythro- 
cyte membranes (from top to 
bottom); lane 2,  1/zg each of 
authentic  GlcCer  from  the 
spleen of a Gaucher's patient, 
asialo-GM2,  and asialo-GMl 
(from top to bottom); lane 3, 
neutral GSL fraction obtained 
from  BMECs  equivalent  to 
1.5 nag protein; lane 4, 2 #g of 
authentic  GlcCer.  The  plate 
was  developed  in the solvent 
system III and the bands were 
visualized  by  spraying  with 
the  orcinol-sulfuric  acid  re- 
agent. 
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[carboxyJ4C]-inulin clearance 
n  rate (#l/min) 
Empty insert  3  12.338 ±  1.081'** 
Cocultured insert 
LT-IgM  5 
LT-IgM +  complement  6 
IgM (control)  4 
IgM (control) +  complement  4 
0.811  ±  0.084** 
0.685  ± 0.260** 
0.213 ±  0.129 
0.220 ±  0.116 
[Carboxyl-~4C]-inulin  clearance  (#l/min)  across  the  empty  insert  and  the 
BMEC/astrocyte cocultured insert was measured following 3 h of 0.1% IgM 
(LT and control, with or without complements) challenge. Asterisk represents 
a significant increase in [carboxyl-14C]-inulin  clearance across membrane over 
controls (**P <0.01, ***P <0.001). Values were expressed as mean +  SD. n, 
number of experiments. 
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tions with and without complements (Fig.  10 b). After in- 
cubation  with  0.1%  LT-IgM,  [t25I]-labeled  LT-IgM  also 
showed an enhanced leakage as compared with the condition 
where incubation was carried out in 0.1% normal IgM with 
[~25I]-labeled normal IgM as a tracer (Fig.  10 c).  ~, 
Fig.  11  shows the  specific release of 51Cr from BMEC  _.'- 
monolayer after incubation with 0.5 and 0.1% of IgM (LT and  _o° 
normal), with or without complements. Specific release of  E 
5~Cr was significantly increased when 0.5%  LT-IgM (9.16 
+  2.16% with complements, 8.48 -l- 1.91% without comple- 
ments) was applied. It was also significantly increased when 
incubated with 0.1%  LT-IgM (8.54  +  2.86%  with comple- 
ments,  11.79 +  3.83%  without complements).  These data 
suggest that the toxic effect of LT-IgM against BMECs was 
independent  of the  complements.  The cytotoxicity of LT- 
IgM was completely suppressed after incubation with a  10- 
fold molar excess of SGPG (Fig.  12 and 13), but the same 
amount of sulfatide had no effect (Fig. 13). Fig. 14 shows the 
immunostaining of living  single  endothelial  cell with  LT- 
IgM, further demonstrating binding of this antibody to intact 
endothelial  cells.  Fig.  15  shows  the  morphology  of the  ® 
BMEC monolayer after incubation with LT-IgM. During the  ~, 
incubation period with LT-IgM, some of the BMECs became  E 
round in shape and the monolayer was disrupted at places. 
A few of them even showed evidence of degeneration, which 
coincided  with  the  increase  release  of  5~Cr in  LT-IgM 
treated cells. The addition of complements did not affect this 
morphological change. 
Discussion 
Because  of the  low  amount  of GSLs  in  BMECs  and  the 
difficulty in obtaining large quantities of "pure" cell popula- 
tions, the GSL composition of BMECs has not been care- 
fully scrutinized before. In our culture methods, which is a 
modification of the methods of Meresse et al.  (.1989) and 
Gordon et al.  (1991),  we started with colonies formed by 
pure BMECs and the purity of these cells was maintained af- 
ter 6-8 passages. In the presence of bFGF and absence of 
contaminating cells (e.g., fibroblasts, astrocytes, pericytes, 
etc.), bovine BMECs multiplied rapidly (10 to 15 times per 
week)  to  afford  sufficient quantities  of cells  for chemical 
analyses.  Endothelial  cells  obtained  from  human  brain 
microvessels would be a better choice for research of human 
diseases, but there are still technical difficulties in obtaining 
sufficient quantities of pure human BMECs for this purpose. 
The exclusion of non-EC contaminants is crucial in this kind 
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Figure 10.  Effect of immunoglobulin  M  on the  permeability  of 
BMEC  monolayers.  (a) Permeability  to [carboxyl-14C]-inulin of 
empty insert (closed square) and BMEC/astrocyte cocultured insert 
(open circle; as designated in Fig. 3). Empty insert showed "o60 
times  high value of [carboxyl-~4C]-inulin influx as compared to 
cocultured  insert,  which  suggested  that  the  cocultured  insert 
provided an excellent barrier for inulin passage.  (b) Changes of 
[carboxyl-~4C]-inulin clearance after incubation with 0.1% LT-IgM 
(with or without complement,  closed and open triangles, respec- 
tively) as compared  with those with 0.1% control  IgM (with or 
without complement, closed and open circles, respectively). Incu- 
bation with LT-IgM resulted in higher [carboxyl-~4C]-inulin  clear- 
ante at all times (p <0.05), regardless of the coincubation of com- 
plements.  (c)  Changes  of [~25I]-IgM clearance  after incubation 
with  0.1% LT-IgM (open triangle; [125I]-conjugated LT-IgM as 
tracer)  and with 0.1% control IgM (open circle; [t25I]-conjugated 
normal IgM as tracer).  Slight but steady IgM leakage was observed 
after LT-IgM challenge, whose value was *~/~ of [carboxyl-~4C]  - 
inulin leakage (see Fig.  10 b). On the other hand, no penetration 
of IgM was observed until 40 min under normal conditions. Error 
bars indicate SEM. 
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Figure 11. Chromium-51 release from BMECs. BMECs incubated 
with LT-IgM showed a significant increase  of 5~Cr release  in all 
four conditions,  suggesting a complement independent BMEC cy- 
totoxicity in patient's IgM. Cells incubated with 0.5 % normal IgM 
(1.24 + 0.58% with complements; 0.58 + 0.44% without comple- 
ments) shows slight but insignificant increase of SlCr release over 
those with 0.1% normal IgM (0.00 +  0.30%  with complements; 
0.34 + 0.25 % without complements). This may imply the possibil- 
ity of  nonspecific IgM toxicity against BMECs in this concentration 
range, but the value is lower than 1/7 of that challenged by patient's 
IgM and it is almost negligible. Asterix represents a significant in- 
crease  in specific release  of 51Cr over its respective control  (*P 
<0.05, **P <0.01). Error bars represent  SEM. 
of study because the GSL content of EC is so low that only 
a small proportion of non-EC contamination may influence 
the  quantitative  results,  especially  in  the  case  of neutral 
GSLs. 
Prior to our study, there were only few reports (Gillard et 
al.,  1987,  1992) presenting the ganglioside composition of 
endothelial cells from human umbilical cord. These investi- 
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Figure  12.  Relationship  between  chromium-51  release  and  IgM 
concentration.  Linear correlation  between  the  51Cr-specific re- 
lease  and the  concentration  of LT-IgM in the  incubation  media 
(closed circles).  Open squares denote the 51Cr-specific release af- 
ter exposure to LT-IgM solution, which was preincubated with a 10- 
fold molar excess of SGPG for 3 h. The toxicity of LT-IgM against 
BMECs  was almost completely  abolished.  Error bars represent 
SEM. 
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Figure  13.  Effect  of  preincubation  of  IgM  with  sulfatide  on 
chromium-51 release from BMECs.  Suppression of the cytotoxic 
effect of patient's IgM by preincubation  with sulfoglycolipids. A 
0.05 % LT-IgM solution was incubated with 10-fold molar excess of 
pure  sulfoglycolipids  for  3  h  and  was  applied  to  the  [51Cr]- 
incorporated  BMEC monolayers. Although SGPG suppressed the 
toxic effect almost completely  (91.1  +  4.1%, p  <0.001), sulfntide 
did not have any effect (8.4 +  28.6%, not significant). Error bars 
represent  SEM. 
gators also reported high amounts of GM3 and SPG, but not 
GM1 nor SGPG.  Relatively high amounts of neutral GSLs 
were also reported; the amount of gangliosides and neutral 
GSLs are almost the same (71 nmol sialic acid vs. 53 nmol 
neutral GSL). They also reported the presence of LacCer, 
Gb3,  Gb4,  paragloboside,  and  Gb5  as  the  major neutral 
GSLs in addition to a smaller amount of GalCer. In contrast, 
we  could detect only GlcCer but  not  other neutral  GSLs 
based  on  TLC  and  GLC  analyses.  The  amount  of total 
GlcCer  in  BMECs  was  extremely  low,  about  1/5  of the 
amount of gangliosides.  The GlcCer in BMECs  appeared 
as doublets which might be due to differences in fatty acid 
compositions  (Rauvala  et  al.,  1976;  Ariga  et  al.,  1982). 
The differences between the  GSL compositions of bovine 
BMECs and human umbilical cord ECs may be attributable 
Figure 14. Immunofluorescent staining of BMEC with anti-SOGL 
antibody.  Fluorescent  micrograph of a  single,  living BMEC  (in 
vitro 16 d) stained with LT-IgM. Bar, 50/~m. 
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micrograph of BMEC monolayer before (A) and after (B) incuba- 
tion with EC media (heat-inactivated)  plus 0.5% LT IgM for 120 
rain. (A) Typical  cobblestone pattern was observed. (B) Some cells 
shrank and the BMEC monolayer showed  disruption of cellular in- 
tercormection at places (arrows). Some  cells showed  vesicular ap- 
pearances (arrowheads). These morphological changes are well 
correlated with the data shown in Figs. 10, 11, and 12. Control IgM 
did not cause any morphological changes. Bar, 100/zm. 
to differences in animal species, site of EC origin, or degree 
of non-EC contaminations. 
The physiological significance of GM3 in BMEC is un- 
known.  However,  GM3  inhibits EGF receptor-associated 
tryosine kinase (Bremer et al., 1986) and is supposed to act 
as a modulator of transmembrane signal transducers in sev- 
eral kinds of cells (Hakomori, 1990). Recently we found that 
exogenously administered GM3(NeuAc) promoted the cy- 
clic AMP-dependent protein kinase and inhibited protein ki- 
nase C  in BMEC  (Kanda et ai.,  1993).  Since the barrier 
function of ECs is considered to be enhanced by cyclic AMP- 
dependent protein kinase and diminished by protein kinase 
C (Stelzner et ai.,  1989;  Oliver,  1990;  Rubin et al.,  1991), 
GM3 may act as a potent mediator of  BBB/BNB function via 
these two kinase systems. 
Another interesting aspect of the present study is the de- 
crease of  the amount of SGPG with the age of  culture. Earlier 
studies have indicated that SGGLs belong to a novel class of 
acidic lipids present primarily in the peripheral nervous tis- 
sues (Chou et al., 1986; Ariga et al., 1987; Kohriyama  et al., 
1987). In the mammalian CNS, SGGLs are known to be de- 
velopmentally regulated, being expressed in embryonic fore- 
brain and disappeared during the postnatal period (Schwar- 
ring et ai.,  1987)  except in murine cerebellum (Chou and 
Jungalwala,  1988) and human optic nerve (Yoshino et al., 
1993).  Recent studies, however, indicated that they are also 
present in nonneural cells or tissues.  Thus,  SGGLs were 
found in dura mater (Kohriyama et ai.,  1987).  In addition, 
we recently reported the presence of SGPG in the microves- 
sel fraction derived from rat cerebral hemisphere (Miyatani 
et al., 1990 b). This latter observation suggests the presence 
of SGPG in BMECs. Since the cerebral microvesscl-cnriched 
fraction  inevitably  contains  nonendothelial  components 
(e.g., pericytes, smooth muscle cells, nerve endings, glial 
cells), further confirmation of the presence of SGPG using 
pure populations of endothelial cells of brain microvascular 
origin seems warranted. 
The concentration of SGPG fell below the detection limit 
of HPTLC-immunostaining after 21 d in vitro. SGPG could 
only be revealed by [ssS]-incorporation  study in cultures as 
old as 38 d old (Fig. 7 B). Such an age-dependent expression 
was not observed for other BMEC glycolipids. It is well 
known that BMECs lose the activity of a BMEC-specific 
marker enzyme, gamma-glutamyl transpeptidase, in older 
cultures and they recover it when treated with astrocyte- 
conditioned media or cocultured with astrocyte (De Bault 
and  Cancilla,  1980).  The  age-dependent  expression  of 
SGPG might also be regulated by similar humoral factors. 
Our present results may also shed light on the role of GSLs 
in the pathogenesis of various autoimmune-mediated neuro- 
logical disorders. It is well known that four gangliotetraose- 
series gangliosides, GM1, GDla, GDlb, and GTlb, are espe- 
cially abundant in the central and peripheral nervous systems 
(Yu and Saito, 1989). In the peripheral nervous system, four 
gangliotetraose-series ganglioside as well as SPG (LM1) oc- 
cur in relative abundance (Chou et al.,  1985; Ariga et al., 
1990; Svennerholm and Fredman, 1990).  SGGLs including 
SGPG and SGLPG are also present in small concentrations 
(Ariga et al.,  1987; Chou and Jungalwala, 1988; Yu et al., 
1990).  Recently the presence of various anti-GSL autoanti- 
bodies have been reported in certain neurologic disorders, 
including  neuropathy  associated  with  monoclonal  gam- 
mopathy (Ariga et al.,  1987; Miyatani et al.,  1987; Duane 
et al.,  1992),  motor neuron disease  (Latov et al.,  1988; 
Yoshino et al., 1992; Sanders et al., 1993),  polyneuropathy 
with multifocal conduction block  (Pestronk et al.,  1988; 
Adams et al.,  1991), Guillain-Barr6 syndrome (Ilyas et al., 
1988,  1992a;  Yiki et al.,  1990),  etc.  The pathogenicity of 
these  antibodies have been  advocated in these disorders; 
however, the question about how the large molecule like im- 
munoglobulins can traverse BBB or BNB has always been 
raised (Yu et at.,  1990, 1993).  Our present study revealed 
that BMECs and the peripheral nervous tissues shared many 
GSLs including SGPG as common antigens; hence, the pre- 
sumed cascade of pathological processes-immunological 
attack of  microvascular endothelial cells, destruction or mal- 
function of BNB, increased permeability across BNB, leak- 
age of immunoglobulins into the endoneurial space, and the 
subsequent immunological attack of peripheral myelin and 
axons  leading  to  their  destruction-can  be  logically ex- 
plained in those patients with anti-glycolipid  antibody. In rats 
sensitized with SGPG, Maeda et al. (1991) described fenes- 
tration of the capillaries in the posterior horn of the lumbar 
spinal cord. 
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demonstrated that this anti-SGGL IgM antibody facilitated 
the  leakage of small  as  well  as  large molecules through 
EC/astrocyte  membrane,  and  was  directly  toxic  against 
BMECs  in  vitro  based  on  the  [carboxyl-l'C]-inulin and 
[125I]-IgM leakage studies and the 51Cr release study.  The 
cytotoxic effect of this antibody depended on its concentra- 
tion in the incubation media and was completely blocked by 
preincubation with a  1G-fold molar excess of SGPG.  Al- 
though cross reactivity of  these IgM antibodies with sulfatide 
was also reported recently (Ilyas et al., 1992b),  preincuba- 
tion with the same amount of sulfatide did not inhibit the 
cytotoxic effect of this antibody. 
At present, it is not clear whether and how immunological 
insults against BMECs actually occur in vivo. There have 
been only a few studies on the pathological changes of en- 
dotheliai cells in IgM neuropathy. Meier et al.  (1984) de- 
scribed the gaps between the adjacent endoneurial cells in a 
case of IgM neuropathy, and Powell  et al.  (1984)  showed 
microvascular changes including the endothelial cytoplasmic 
enlargement occasionally obliterating the vessel lumen and 
intracytoplasmic  actin-like  filaments  in  dysglobulinemic 
neuropathies.  Detailed  characterization of the  antibodies 
was not performed. In both reports, pathological changes in 
endothelial cells were minimal and are completely different 
from those of acute inflammatory changes presumably due 
to the deposition of circulating immune complexes, typically 
observed in vessels in collagen diseases with vasculitis such 
as periarteritis nodosa (Corm and Dyck, 1984).  In the pres- 
ent investigation, no qualitative or quantitative difference of 
BMEC damages were observed between the conditions with 
complements and those without complements. These in vivo 
and in vitro observations suggest that immunological attack 
against BMECs occurs independent of the presence of com- 
plements in this disorder, and the underlying immunological 
mechanism is different from those usually encountered in 
humoral immunity, namely, a  complement-mediated cell- 
lyric process or deposition of  circulating immune complexes. 
In view of a certain similarity in the function for glycopro- 
teins possessing the HNK-1  epitope, namely, N-CAM, J1, 
and L1  for nervous system cell adhesion and neurothelin 
(Schlosshauer and Herzog, 1990) for endothelial cell adhe- 
sion with BBB formation, it is possible that SGPG is related 
to the adhesion of BMECs including BBB/BNB formation. 
SGGLs were also found to bind laminin, an extracellular 
matrix glycoprotein involved in cellular adhesion (Mohan et 
al., 1990). Hence, immunological  block of SGPG epitope by 
IgM antibody may result in the loss of cellular intercon- 
nection among BMECs and finally cell death, as shown in 
our present experiments. Recently, Needham and Schnaar 
(1993) reported that SGGLs act as ligands for L- and P-selec- 
tins, but not for E-selectin. Because selections are involved 
in  the  interaction  between  leukocytes  and  vascular  en- 
dothelial ceils leading to lymphocyte homing, platelet bind- 
ing, and neutrophil extravasation (Lawrence and Springer, 
1991; Foxall et al., 1992),  SGPG on the surface of BMECs 
might play an important role in inflammatory or demyelinat- 
ing diseases of the central and peripheral nervous systems. 
It may support the selective adhesion of a desired subpopula- 
tion of leukocytes expressing L- or P-selectin (Needham and 
Schnaar, 1993), but this mechanism can be harmful in patho- 
logical conditions such as inflammatory or demyelinating 
neurological disorders because it will allow the cytotoxic 
leukocytes to  enter  into  the  CNS  or  PNS  parenchyma. 
L-selectin-mediated attachment of lymphocytes to myelin- 
ated tracts of CNS was also reported (Huang et al., 1991). 
In this regard, blockage of  leukocyte/endothelial  cell connec- 
tion by applying excess amount of polysaccharides (Willen- 
borg and Parish, 1988) or by administration of monoclonal 
antibodies to block these oligosaccharide epitopes might be 
an effective therapeutic strategy. However, the toxic effect of 
anti-SGPG antibody against BMECs as shown in this study 
should also be noted. Further studies are now in progress to 
clarify the functional aspect of SGPG in BMECs. 
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